Phenotypes Associated with This Genotype

Genotype
MGI:5559904

• Allelic Composition: Tg(PDGFB-LRRK2*G2019S)32Hlw/?
• Genetic Background: FVB/N-Tg(PDGFB-LRRK2*G2019S)32Hlw

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

decreased locomotor activity ( J:204793 )

• 12 month old mice show a reduction in spontaneous ambulatory activity and are less active

• 12 month old mice treated with methyl L-DOPA show rescue of hypoactivity

bradykinesia ( J:204793 )

• 12 and 16 month old mice show an increase in the time required to perform the pole test, indicating impaired motor performance and bradykinesia

nervous system

abnormal substantia nigra pars compacta morphology ( J:204793 )

• progressive degeneration of substantia nigra pars compacta dopaminergic neurons starting around 12 months of age

tau protein deposits ( J:204793 )

• mice show accumulation of hyperphosphorylated microtubule-associated protein tau in the brain at 12 months of age

• however, Lewy bodies or Lewy neurites are not seen in the substantia nigra

abnormal dopaminergic neuron morphology ( J:204793 )

• striatal uptake of a tracer of presynaptic dopamine transporter is decreased in 12 month old mice and density of TH-immunoreactive staining is decreased in striatal sections indicating degeneration of nigrostriatal dopaminergic terminals

neuron degeneration ( J:204793 )

• progressive degeneration of substantia nigra pars compacta dopaminergic neurons starting around 12 months of age

• however, neuronal death is not seen in the cerebral cortex, hippocampus or striatum at 12 or 16 months of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Parkinson's disease 8		DOID:0060371	OMIM:607060	J:204793